← Leaderboards
Bihui Hilda Ye
Yeshiva University
$5,265,770
Attributed
$5,481,755
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $750.5K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,481,755 · 3
By mechanism
R01$5,049,785 · 2
R21$431,970 · 1
Top collaborators
- Gregoire Stephane Lauvau2 shared
Most similar at Yeshiva University
Same institution · by research overlap
- Matthew D Scharff$14,553,536
Others in their field
Top investigators on “Transcription Factor”
- Michael P Snyder · Yale University$110,571,583
- Richard M Myers · Hudson-Alpha Institute For Biotechnology$57,320,347
- Eric J Nestler · Icahn School Of Medicine At Mount Sinai$55,523,574
- Angela M. Gronenborn · Diabetes, Digestive, Kidney Diseases$45,640,184
- Richard K. Wilson · Washington University$45,224,621
- Deborah Nickerson · University Of Washington$35,131,320
Research focus
Transcription FactorPatternBcl6 GeneDesignResponseB-LymphocytesPhenotypeMutationCell ProliferationGeneticBiologySignal PathwayPlayGenesPathway InteractionsChromatinExonsUniversitiesTreatment OutcomeCarcinogenesisGene Induction /RepressionB Cell LymphomaGene MutationGenetically Modified Animals
Grant awards (15)
Epigenetic Alterations and Targeted Therapies in North American ATLL$551,261
R01 · FY2025 · CA · contact PI
Functional state of CD8+ T cell immunity in adult T-cell leukemia/lymphoma$196,350
R21 · FY2025 · CA · contact PI
Epigenetic Alterations and Targeted Therapies in North American ATLL$514,837
R01 · FY2024 · CA · contact PI
Functional state of CD8+ T cell immunity in adult T-cell leukemia/lymphoma$235,620
R21 · FY2024 · CA · contact PI
Epigenetic Alterations and Targeted Therapies in North American ATLL$552,413
R01 · FY2023 · CA · contact PI
Role of the BCL 6 Proto Oncogene in B Cell Lymphomas$364,967
R01 · FY2010 · CA · contact PI
Role of the BCL 6 Proto Oncogene in B Cell Lymphomas$357,886
R01 · FY2009 · CA · contact PI
Role of the BCL 6 Proto Oncogene in B Cell Lymphomas$347,533
R01 · FY2008 · CA · contact PI
Role of the BCL 6 Proto Oncogene in B Cell Lymphomas$344,171
R01 · FY2007 · CA · contact PI
Role of the BCL 6 Proto Oncogene in B Cell Lymphomas$344,094
R01 · FY2006 · CA · contact PI
ROLE OF THE BCL 6 PROTO ONCOGENE IN B CELL LYMPHOMAS$353,764
R01 · FY2004 · CA
ROLE OF THE BCL 6 PROTO ONCOGENE IN B CELL LYMPHOMAS$343,461
R01 · FY2003 · CA
ROLE OF THE BCL 6 PROTO ONCOGENE IN B CELL LYMPHOMAS$333,625
R01 · FY2002 · CA
ROLE OF THE BCL 6 PROTO ONCOGENE IN B CELL LYMPHOMAS$324,716
R01 · FY2001 · CA
ROLE OF THE BCL 6 PROTO ONCOGENE IN B CELL LYMPHOMAS$317,057
R01 · FY2000 · CA